Xilio Therapeutics Inc
Research Xilio Therapeutics Inc (XLO) on Bullrun: market cap USD 53.60M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerXLO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 53.60M
- Financial periodFY2025
- RevenueUSD 43.77M
- Revenue growth589.9%
- Net income-USD 35.04M
- Free cash flow-USD 5.51M
Valuation Snapshot
latest market cap is USD 53.60M.
About Xilio Therapeutics Inc
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors;
Frequently asked questions
What is Xilio Therapeutics Inc's market cap?
Xilio Therapeutics Inc's market capitalization is USD 53.60M.
What does Xilio Therapeutics Inc do?
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer;